4.15
+0.44(+11.86%)
Currency In USD
| Previous Close | 3.71 |
| Open | 3.72 |
| Day High | 4.19 |
| Day Low | 3.68 |
| 52-Week High | 28.93 |
| 52-Week Low | 2.24 |
| Volume | 601,733 |
| Average Volume | 551,034 |
| Market Cap | 192.25M |
| PE | -1.31 |
| EPS | -3.18 |
| Moving Average 50 Days | 3.68 |
| Moving Average 200 Days | 5.96 |
| Change | 0.44 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $102.47 as of July 01, 2025 at a share price of $4.15. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $596.26 as of July 01, 2025 at a share price of $4.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
GlobeNewswire Inc.
May 08, 2025 8:05 PM GMT
Enrolled first patients in first 4D-150 Phase 3 clinical trial (4FRONT-1) in wet AMD, with over 50 clinical trial sites open to dateInitiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME
GlobeNewswire Inc.
May 01, 2025 12:00 PM GMT
EMERYVILLE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment
4DMT Announces New Employment Inducement Grants
GlobeNewswire Inc.
Apr 11, 2025 8:05 PM GMT
EMERYVILLE, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatme